Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

Published:2013-10-10 Issue:2 Volume:32 Page:213-226
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

King Constance,Diaz Henry,Barnard Darlene,Barda David,Clawson David,Blosser Wayne,Cox Karen,Guo Sherry,Marshall Mark

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-013-0036-7.pdf

Reference33 articles.

1. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res Off J Am Assoc Cancer Res 16(2):376–383. doi: 10.1158/1078-0432.CCR-09-1029

2. Carrassa L, Damia G (2011) Unleashing Chk1 in cancer therapy. Cell Cycle 10(13):2121–2128

3. Nam EA, Cortez D (2011) ATR signalling: more than meeting at the fork. Biochem J 436(3):527–536. doi: 10.1042/BJ20102162

4. Garrett MD, Collins I (2011) Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32(5):308–316. doi: 10.1016/j.tips.2011.02.014

5. Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A (2006) Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 5(21):2543–2547

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy;Cancers;2024-08-29

2. Functions and inhibitors of CHK1 in cancer therapy;Medicine in Drug Discovery;2024-06

3. The luciferase-based in vivo protein–protein interaction assay revealed that CHK1 promotes PP2A and PME-1 interaction;Journal of Biological Chemistry;2024-05

4. Novel Amidine Derivative K1586 Sensitizes Colorectal Cancer Cells to Ionizing Radiation by Inducing Chk1 Instability;International Journal of Molecular Sciences;2024-04-16

5. Targeting the DNA Damage Response for Cancer Therapy;International Journal of Molecular Sciences;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3